



OPEN

Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study

Silja A. S. Salo¹, Eila Lantto^{2,4}, Eric Robinson⁵, Marjukka Myllärniemi^{2,6}, Sanna Laaksonen^{2,7}, Jarmo A. Salo^{2,3}, Tuomo Rantanen^{1,8,9}✉ & Ilkka Ilonen^{2,3,9}

Malignant peritoneal mesothelioma (MPeM) is a rare cancer of the mesothelial cells of the peritoneum. Computed tomography (CT) is considered the standard for first-line imaging of MPeM, diagnosis and risk stratification remains challenging. Peritoneal cancer index (PCI), as assessed by CT, is utilized in the prognostic assessment of other malignant intra-abdominal conditions; however, there is limited data concerning the utility of PCI in the diagnosis and workup of MPeM. We studied a retrospective cohort of all patients diagnosed with MPeM from 2000 to 2012 in Finland. CT and magnetic resonance imaging (MRI) were reviewed and scored by an experienced and blinded, board-certified abdominal radiologist. Additional clinical data and outcomes were obtained from Finnish Cancer Registry (FCR), the Workers' Compensations Center (WCC), and Statistics Finland (SF). Abdominal CT or MRI was available for 53 of 90 patients. The median radiographic PCI was 25. PCI score was correlated with overall survival ($p = 0.004$, $\text{Exp}(B) = 1.064$, 95% CI 1.020–1.110). PCI score ≥ 30 was associated with worse survival ($p = 0.002$), while PCI ≤ 19 was associated with improved overall survival ($p = 0.001$). Our study indicates that radiological PCI is prognostic in MPeM and should be assessed during radiographic workup and integrated into clinical decision-making.

Malignant peritoneal mesothelioma (MPeM) is a rare cancer of the mesothelial cells of peritoneum, representing 7–30% of all mesothelioma diagnoses.¹ Signs and symptoms of MPeM are non-specific and include abdominal pain, abdominal distension, and weight loss. Given the rarity of the diagnosis and the non-specific presentation, diagnosis is often delayed.^{2,3} Previous reports have indicated median time of 4–6 months between initial presentation and diagnosis.⁴

Computed tomography (CT) of the chest, abdomen, and pelvis is the first-line imaging modality in the diagnostic workup of MPeM.⁵ Ascites, peritoneal thickening, omental disease, small bowel involvement and solid and cystic masses are typical of MPeM on CT.^{6–8} However, the sensitivity and specificity of CT in the diagnosis of MPeM is not described in the literature. The role of PET-CT in the diagnosis and workup of MPeM is likewise unclear.⁹ Peritoneal mesothelioma is not well suited to traditional classification schemes like the TNM staging due to the rarity of distant metastases and the difficulty in discerning the full extent primary tumor versus local/regional spread. Several staging systems for MPeM have been proposed but to date have not been widely adopted.¹⁰ Peritoneal cancer index (PCI) is a measure of disease spread developed for peritoneal carcinomatosis

¹Department of Surgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. ²Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland. ³Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland. ⁴Department of Radiology, Helsinki University Hospital, Helsinki, Finland. ⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁶Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland. ⁷Department of Pathology, HUSLAB, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ⁸Department of Surgery, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland. ⁹These authors contributed equally: Tuomo Rantanen and Ilkka Ilonen. ✉email: tuomo.rantanen@kuh.fi

Region	Location	Lesion size (score)
0	Central	0–3
1	Right upper	0–3
2	Epigastrium	0–3
3	Left upper	0–3
4	Left flank	0–3
5	Left lower	0–3
6	Pelvis	0–3
7	Right lower	0–3
8	Right flank	0–3
9	Upper jejunum	0–3
10	Lower jejunum	0–3
11	Upper ileum	0–3
12	Lower ileum	0–3
<i>Total</i>		0–39

Table 1. The Peritoneal Cancer Index Scoring system⁹.

that can be evaluated surgically during laparotomy or radiographically by CT. PCI is scored across 13 abdominal regions with the composite score reflecting both tumor size and distribution (Table 1)^{10,11} The primary aim of our study was to evaluate the prognostic value of radiologic PCI and other clinical and radiographic features in a population-based cohort of patients presenting with MPeM over a 12-year period.

Materials and methods

Patients. We studied all patients diagnosed with primary MPeM in Finland from January 1st, 2000 to December 31st, 2012. Patients were identified through the Finnish Cancer Registry (FCR) using WHO ICD-3.O codes as previously described.^{12,13} Additional data concerning asbestos exposure and survival status (current to May 2018) were collected from the Workers' Compensations Center (WCC) and Statistics Finland (SF), respectively. In total, 90 patients were diagnosed with MPeM over the study period. Abdominal CT and/or MRI were available for 53 of 90 patients (58.8%). This study was approved by the Ethical Committee of Helsinki and Uusimaa Hospital District. Because of retrospective study the informed consent was waived by the Ethical Committee of Helsinki and Uusimaa Hospital District.

Radiographic assessment. CT and magnetic resonance imaging (MRI) images were collected from the presenting facility. Abdominal CT images were available for 52 of 53 patients (98.1%); one patient (1.9%) underwent abdominal MRI. Thirty-five of 53 radiological investigations (66.0%) were within 30 days of the tissue diagnosis. Twelve of 53 (22.6%) CT studies included only the abdominal region. Images were re-analyzed by an experienced board-certified abdominal radiologist (E.L.). The radiologist was aware of the MPeM diagnosis but blinded to the original radiology report and other clinical details. In addition to assessing the PCI score, images were reviewed for ascites, pleural effusion, regional/distant lymph nodes, and extra-abdominal organ metastases. Lymph nodes with a radiological short axis of 10 mm or greater were considered malignant. Pleural effusion was not classified as evidence of extra-abdominal spread; pleural thickening was considered as evidence of metastatic deposit. Lymph node metastases included inguinal, umbilical, supraclavicular, paracardial, mediastinal, parailiacal, and subcarinal lymph nodes.

Radiological PCI score was calculated as previously described.^{10,11} Disease spread was assessed across 13 discrete anatomical locations. The PCI scoring scheme incorporates Lesion Size according to the following scheme: (A) *zero points* for the absence of identifiable disease; (B) *one point* for lesions 0.5 cm or smaller; (C) *two points* for lesions bigger than 0.5 cm but smaller than 5 cm; and (D) *three points* for lesions or tumor mass 5 cm or bigger. If changes to the bowel surface were noted, such as invasion of the bowel wall, the region was also scored as three points.

Statistical analysis. Data was collected and analyzed by IBM SPSS Statistics versions 24 and 25 for Mac. Images were viewed by Agfa IMPAX. Tables and Figures were generated with IBM SPSS Statistics and Microsoft Excel. Fisher's exact test and Pearson's Chi-Square Test were used to compare study variables across subgroup. Cox regression proportional hazard analysis was used to assess the prognostic value of clinical and radiographic characteristics including PCI. A p value < 0.05 was considered statistically significant. We established a categorical threshold (e.g. 0–19, low PCI group, and 20–39, high PCI group) to determine if PCI classification could provide meaningfully risk stratify patients at presentation.

Results

The final study population included 53 patients (38 men, 15 women), whose baseline characteristics are presented in Table 2. Across all patients the overall median PCI was 25 (range 0–39). PCI score was not significantly associated with ascites ($p = 0.082$), lymph node or extra-abdominal metastases ($p = 0.295$), pleural effusion ($p = 0.240$),

Characteristic	Male (n = 38)	Female (n = 15)	Total (n = 53)	p value
Age, median (SD)	66	65	66	–
Asbestos exposure				
Yes	13 (34.2%)	2 (13.3%)	15 (28.3%)	p = 0.103
No	17 (44.7%)	10 (66.7%)	27 (50.9%)	
Unknown	8 (21.1%)	3 (20.0%)	11 (20.8%)	
Histological subtype				
Epithelial	16 (42.1%)	6 (40.0%)	22 (41.5%)	p = 0.798
Sarcomatoid	1 (2.6%)	1 (6.7%)	2 (3.8%)	
Biphasic	1 (2.6%)	1 (6.7%)	2 (3.8%)	
Unknown	20 (52.6%)	7 (46.7%)	27 (50.9%)	
Diagnostic method				
Biopsy	27 (71.1%)	14 (93.3%)	41 (77.4%)	p = 0.119
Autopsy	11 (28.9%)	1 (6.7%)	12 (22.6%)	
Median PCI (range)	24.0 (0–38)	25.5 (0–39)	25 (0–39)	p = 0.959
Ascites				
Present	29 (76.3%)	13 (86.6%)	42 (81.1%)	p = 0.403
Absent	9 (23.7%)	2 (13.3%)	11 (20.8%)	
Pleural effusion				
Present	11 (28.9%)	2 (13.3%)	13 (24.5%)	p = 0.135
Absent	21 (55.3%)	7 (46.7%)	28 (52.9%)	
Only abdominal imaging	6 (15.8%)	6 (40.0%)	12 (22.6%)	

Table 2. Clinical, demographic, and diagnostic characteristics by sex.

Characteristic	PCI (0–19)	PCI (20–39)	All cases	p value
Age, median (SD)	66	65.5	66	p = 0.846
Asbestos exposure				
Yes	3 (17.6%)	10 (27.8%)	13 (24.5%)	p = 0.252
No	12 (70.6%)	17 (47.2%)	29 (54.7%)	
Unknown	2 (11.8%)	9 (25.0%)	11 (20.8%)	
Histological subtype				
Epithelial	7 (41.2%)	15 (41.7%)	22 (41.5%)	p = 0.881
Sarcomatoid	1 (5.9%)	1 (2.8%)	2 (3.8%)	
Biphasic	1 (5.9%)	1 (2.8%)	2 (3.8%)	
Unknown	8 (47.1%)	19 (52.8%)	27 (50.9%)	
Initial treatment				
Surgery/CRS +/- HIPEC*	3 (17.6%)	2 (5.6%)	5 (9.4%)	p = 0.196
Chemotherapy +/- radiation	10 (58.8%)	15 (41.7%)	25 (47.2%)	
Palliative	1 (5.9%)	3 (8.3%)	4 (7.5%)	
No treatment	3 (17.6%)	16 (44.4%)	19 (35.8%)	
Median survival, months (range)	57 (2–192)	12 (0–92)	9 (0–192)	p = 0.001**

Table 3. Clinical, demographic, and diagnostic characteristics according to PCI Score. *Cytoreductive surgery; +/- HIPEC and/or chemo-radiation; **Cox regression.

or asbestos exposure ($p = 0.252$). Across all patients the overall median PCI was 25 (range 0–39). There was no significant difference between men and women with respect to median PCI, asbestos exposure, pleural effusion, or ascites (see Tables 2, 3).

The PCI score was associated with worse overall survival ($p = 0.04$). For patients in low PCI group (17/53; 32.1%), median survival was 43 months (range 2–192); whereas for patients in high PCI group (36/53; 67.9%), median survival was 6 months (range 0–92). This difference in survival was statistically significant measured by Cox Regression ($p = 0.001$; Fig. 1). The 1-year survival rate for low PCI group was 58.8% (10/17) while the 2- and 5-year survival rate were 52.9% (9/17) and 23.5% (4/17), respectively. Among the high PCI group, the 1-, 2-, and 5-year survival were 22.2% (8/36), 8.3% (3/36) and 5.6% (2/36), respectively.

The median PCI was 25 (range 0–36) among patients with asbestosis exposure and 25 (range 0–39) among patients with no suspected occupational exposure.




Figure 1. Kaplan–Meier survival curves according to low PCI group (PCI score range of 0–19) versus high PCI group (20–39) ($p=0.001$).




Figure 2. Kaplan–Meier survival curves among patients with and without ascites ($p>0.05$).

Patients with ascites had median survival of 7 months, compared to 39 months for patients without ascites (Fig. 2; $p>0.05$). Patients with pleural effusion had median survival of 8 months, compared to 9 months for patients without ascites ($p>0.05$). Thirteen patients of the 41 patients who had body CT (31.7%) had pleural effusion in imaging; nine of 13 (69.2%) cases were unilaterally and four of fourteen (28.6%) were bilateral. Patients with extra-abdominal or lymph node metastases had median survival of 8 months, as well as 8 months for patients without metastases ($p>0.05$). Among non-imaged patients, median survival after diagnosis of 2 months

Year	Author	Staging system
1996	Jacquet P, Sugarbaker PH ⁹	Peritoneal cancer index (PCI)
2011	Yan et al. ¹⁰	Novel TNM staging system
2013	Schaub et al. ¹³	Novel nomogram for 3- and 5-year overall survival
2014	Magge et al. ¹²	The Dutch simplified peritoneal cancer index (SPCI)
2005	Yan et al. ^{14,15}	Classification scheme of small bowel involvement (class I–III)

Table 4. Summary of previous reports of PCI and proposed staging systems in MPeM.




Figure 3. A patient with a solitary 7 cm tumor in region 2. The tumor can be seen in the medial abdomen anteriorly between the left liver lobe and the ventricle. Total Peritoneal cancer index 3.

(range 0–68) was worse compared to patients who were imaged, whose median survival after diagnosis was 8 months (range 0–192) ($p=0.001$). There was a significant difference between survival.

Discussion

The results of this study suggest that the radiological peritoneal cancer index has significant prognostic value in patients with MPeM. PCI had a statistically significant association with survival and categorical classification meaningfully stratified patients according to survival after diagnosis.

MPeM is a challenging diagnosis with a historically intractable course. Current treatments paradigms are not well established but CRS with HIPEC has emerged as the most promising modality. The potential utility of PCI and other staging schemes is in guiding clinical care and selecting appropriate candidates for treatment modalities like CRS with HIPEC. To that end, Yan et al. have proposed a novel TNM staging system for diffuse MPeM patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).¹⁴ Their classification scheme was similar to the categorical analysis of PCI applied in this study. They considered PCI Score as the "T" component in their TNM staging system and divided PCI into four categories: T1 (0–10), T2 (11–20), T3 (21–30) and T4 (31–39).¹⁴ Magge et al. have studied prognostic factors of MPeM and applied the Dutch simplified peritoneal cancer index (SPCI). The Dutch Simplified Peritoneal Cancer Index (SPCI) assesses disease spread across seven abdominal regions and applies a score based on the largest tumor nodule in each region (no tumor = 0; < 2 cm = 1; 2–5 cm = 2; > 5 cm = 3) with a maximum score of 21. That study found SPCI > 15 to be associated with worse survival.¹⁵ Schaub et al. developed a novel nomogram for 3- and 5-year overall survival in patients treated with CRS and HIPEC. They considered patients with a PCI score of 10 or less as low risk, those with a PCI score of 11 to 19 as moderate risk, and those with a PCI score greater than 19 as high risk.¹⁶ Finally, Yan et al. have described a classification scheme of small bowel involvement (class I–III) (Table 4), which can help assess the operability of MPeM patients.^{17,18} To our knowledge, our investigation is the first population-based study of PCI in MPeM. Our results support to the generalizability of these previous studies by demonstrating the prognostic utility of PCI in a population-based cohort (Figs. 3, 4).^{14,19,20}

Additional radiologic findings in MPeM include ascites, pleural effusion, and extra-abdominal metastases. Ascites is a common radiographic finding and was observed in 79.2% of the patients.²¹ While the median survival of patients with ascites was 7 months—compared to 39-months in patients without ascites—this result was not




Figure 4. A patient with wide tumor growth. Tumor involvement in the liver hilus (A) and inferior apex and following the mesentery (B) and peritoneal surface (C). Total peritoneal cancer index 38.

significant. Our study was likely underpowered to detect such a difference given the relative small proportion of patients with absent ascites and size of the study cohort. Nevertheless, the association with absent ascites and improved survival has been previously reported.²² Female gender, age < 60, epithelioid subtype, Ki-67 expression < 10%, and the absence of lymphatic spread are also considered good prognostic features.^{14,16,23,24}

The disease course of MPeM is atypical in the sense that there is no discrete primary site. Instead, thousands of mesothelioma nodules are observed across the peritoneum at time of diagnosis. Malignant ascites and local–regional invasion are common. Lymph node involvement (5–10%) and extra-abdominal metastases (3–5%) are considered relatively rare complications associated with advanced late stage disease.^{9,21} However, in this study cohort 26.4% of patients were observed to have evidence of lymph node involvement and/or extra-abdominal metastases. As we were unable to confirm lymph node spread pathologically in most cases, it is possible that this result is biased by our reliance on radiographic staging alone. However, it may also be a reflection of delays in the diagnosis and care of patients with MPeM in Finland. As a small country with a population of 5.5-million and no dedicated specialty centers for peritoneal mesothelioma, these results highlight the need for increased awareness and additional resources around MPeM.¹²

There are several limitations to this investigation. There was a statistically significant difference in survival among imaged and non-imaged patients, which probably concludes of the fact that the majority of non-imaged patients were diagnosed at autopsy and therefore not imaged. The number of patients in our study remains small. Information concerning treatment response is partly scarce, since a proportion of the patients' medical records have been removed for privacy protection reasons after storing for 10 years. In addition, cross-sections of CT images were wider in older CT images, which made assessment of the bowel surface and diaphragm more challenging. Surgical PCI was not studied since only a minority of patients underwent surgery. Strengths of this investigation include the 13-year-long study period and the reliability of data from the Finnish Cancer Registry (FCR).²⁵ In addition, this is the first population-based cohort studies concerning the prognostic role of radiological PCI of primary MPeM to date. Potential future directions include comparing radiological pre-operative PCI to surgical PCI. Ultimately, evaluation of PCI and other staging schemes in a prospective setting will be necessary to fully assess their application in guiding clinical management including.

Received: 21 December 2019; Accepted: 20 July 2020

Published online: 06 August 2020

References

- Kim, J., Bhagwandin, S. & Labow, D. M. Malignant peritoneal mesothelioma: a review. *Ann. Transl. Med.* **5**(11), 236. <https://doi.org/10.21037/atm.2017.03.96> (2017).
- Acherman, Y. I., Welch, L. S., Bromley, C. M. & Sugarbaker, P. H. Clinical presentation of peritoneal mesothelioma. *Tumori* **89**(3), 269–273 (2003).
- Chua, T. C., Yan, T. D. & Morris, D. L. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. *J. Surg. Oncol.* **99**(2), 109–113. <https://doi.org/10.1002/jso.21177> (2009).
- Kaya, H. *et al.* Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. *Neoplasma* **61**(4), 433–438. https://doi.org/10.4149/neo_2014_053 (2014).
- Garcia-Fadrique, A. *et al.* Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: A review. *J. Gastrointest. Oncol.* **8**(5), 915–924. <https://doi.org/10.21037/jgo.2017.08.01> (2017).
- Ros, P. R., Yuschok, T. J., Buck, J. L., Shekitka, K. M. & Kaude, J. V. Peritoneal mesothelioma. Radiologic appearances correlated with histology. *Acta Radiol.* **32**(5), 355–358 (1991).
- Reuter, K. *et al.* Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. *AJR Am. J. Roentgenol.* **140**(6), 1189–1194. <https://doi.org/10.2214/ajr.140.6.1189> (1983).
- Chandramohan, A., Thrower, A., Shah, N. & Mohamed, F. Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. *Br. J. Radiol.* **90**(1079), 20170361. <https://doi.org/10.1259/bjr.20170361> (2017).
- Deraco, M., Bartlett, D., Kusamura, S. & Baratti, D. Consensus statement on peritoneal mesothelioma. *J. Surg. Oncol.* **98**(4), 268–272. <https://doi.org/10.1002/jso.21055> (2008).

10. Jacquet, P. & Sugarbaker, P. H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat. Res.* **82**, 359–374 (1996).
11. Jacquet, P. & Sugarbaker, P. H. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. *J. Exp. Clin. Cancer Res.* **15**, 49–58 (1996).
12. Salo, S. A. S. *et al.* Epidemiology of malignant peritoneal mesothelioma: a population-based study. *Cancer Epidemiol.* **51**, 81–86 (2017).
13. Salo, S. A. S. *et al.* Malignant peritoneal mesothelioma: treatment options and survival. *Anticancer Res.* **39**(2), 839–845. <https://doi.org/10.21873/anticancer.13183> (2019).
14. Yan, T. D. *et al.* A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. *Cancer* **117**(9), 1855–1863. <https://doi.org/10.1002/cncr.25640> (2011).
15. Magge, D. *et al.* Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. *Ann. Surg. Oncol.* **21**(4), 1159–1165. <https://doi.org/10.1245/s10434-013-3358-y> (2014).
16. Schaub, N. P. *et al.* A novel nomogram for peritoneal mesothelioma predicts survival. *Ann. Surg. Oncol.* **20**(2), 555–561. <https://doi.org/10.1245/s10434-012-2651-5> (2013).
17. Yan, T. D., Haveric, N., Carmignani, C. P., Chang, D. & Sugarbaker, P. H. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. *Cancer* **103**(4), 839–849. <https://doi.org/10.1002/cncr.20836> (2005).
18. Yan, T. D., Haveric, N., Carmignani, C. P., Bromley, C. M. & Sugarbaker, P. H. Computed tomographic characterization of malignant peritoneal mesothelioma. *Tumori* **91**(5), 394–400 (2005).
19. Helm, J. H. *et al.* Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. *Ann. Surg. Oncol.* **22**(5), 1686–1693. <https://doi.org/10.1245/s10434-014-3978-x> (2015).
20. Sugarbaker, P. H. Update on the management of malignant peritoneal mesothelioma. *Transl. Lung Cancer Res.* **7**(5), 599–608. <https://doi.org/10.21037/tlcr.2018.08.03> (2018).
21. Enomoto, L. M., Shen, P., Levine, E. A. & Votanopoulos, K. I. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. *Cancer Manag. Res.* **11**, 4231–4241. <https://doi.org/10.2147/CMAR.S170300> (2019).
22. Jin, S. *et al.* Predictive factors analysis for malignant peritoneal mesothelioma. *J. Gastrointest. Surg.* **19**(2), 319–326. <https://doi.org/10.1007/s11605-014-2664-4> (2015).
23. Deraco, M. *et al.* Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. *Ann. Surg. Oncol.* **13**(2), 229–237. <https://doi.org/10.1245/ASO.2006.03.045> (2006).
24. Yan, T. D. *et al.* Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J. Clin. Oncol.* **27**(36), 6237–6242. <https://doi.org/10.1200/JCO.2009.23.9640> (2009).
25. Teppo, L., Pukkala, E. & Lehtonen, M. Data quality and quality control of a population-based cancer registry. Experience in Finland. *Acta Oncol.* **33**(4), 365–369 (1994).

Acknowledgements

Silja Salo has received a personal grant from the Finnish Cultural Foundation's North Savo Regional Fund. The study was supported by the Cancer Society of Finland and the Finnish Work Environment Fund.

Author contributions

S.S., I.I., E.R., J.S. and T.R. wrote the main manuscript and E.L. prepared figures. All authors (S.S., I.I., E.L., E.R., M.M., S.L., J.S. and T.R.) reviewed the manuscript. Because of retrospective study the informed consent was waived by the Ethical committee.

Competing interest

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to T.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020